Skip to main content
PepGen Inc. logo

PepGen Inc. — Investor Relations & Filings

Ticker · PEPG ISIN · US7133171055 US Professional, scientific and technical activities
Open in API
Filings indexed 272 across all filing types
Latest filing 2026-05-21 Report Publication Anno…
Country US United States of America
Listing US PEPG

About PepGen Inc.

https://pepgen.com

PepGen Inc. is a clinical-stage biotechnology company focused on developing the next generation of oligonucleotide therapeutics. The company's proprietary Enhanced Delivery Oligonucleotide (EDO) technology is designed to safely and effectively deliver drug candidates to target the root cause of severe neuromuscular and neurological diseases. PepGen is advancing a pipeline of disease-modifying therapies with the goal of transforming treatment for patients with debilitating genetic disorders.

Recent filings

Filing Released Lang Actions
8-K
Report Publication Announcement Classification · 95% confidence The document is a Form 8-K current report announcing that PepGen’s updated corporate presentation is furnished as Exhibit 99.1. It does not contain the presentation itself or substantive financial data, but simply notes the report is attached. Per the “menu vs meal” rule for short documents announcing report attachments, this is a Report Publication Announcement.
2026-05-21 English
8-K - PEPGEN INC. (0001835597) (Filer)
Investor Presentation Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated March 4, 2026, for PepGen Inc. It specifically mentions an update to the Corporate Presentation (Exhibit 99.1) being furnished. The text states that the information is being furnished and not filed, and it includes a corporate presentation as an exhibit. The document length is 3526 characters, which is relatively short and consistent with an announcement rather than a full report. The key phrase 'updated its Corporate Presentation' and the presence of Exhibit 99.1 labeled as 'Corporate Presentation' indicate this is an investor presentation update. According to the filing definitions, an investor presentation focusing on financials, strategy, and market position is classified as IP. Therefore, the document is best classified as an Investor Presentation (IP).
2026-03-04 English
10-K - PEPGEN INC. (0001835597) (Filer)
Annual Report FY 2025
2026-03-04 English
8-K - PEPGEN INC. (0001835597) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text includes announcements of financial results for the year ended December 31, 2025, but it is not the full annual report or detailed financial statements. Instead, it references a press release with financial results and a regulatory update about a clinical hold notice. The document is relatively short (4275 characters) and primarily serves as an announcement of these events rather than containing comprehensive financial data or management discussion. Therefore, it fits best as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories and includes current reports like Form 8-K filings that announce events or updates without full financial reports.
2026-03-04 English
4 - PEPGEN INC. (0001835597) (Filer)
Director's Dealing
2026-03-02 English
4 - PEPGEN INC. (0001835597) (Filer)
Director's Dealing
2026-03-02 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.